Cargene Biopharma welcomes Kathy He as CEO, to accelerate the development of new therapeutic oligonucleotides

SINGAPORE, BOSTON and SHANGHAI, June 28, 2022 /PRNewswire/ — Cargene Biopharma Inc. (“Cargene”, the “Company”), a biopharmaceutical company developing oligonucleotide therapies for liver and ophthalmic disorders, is delighted to welcome Kathy He, a seasoned biopharmaceutical industry executive, to join the Company as Chief Executive Officer and member of the Board of Directors. Kathy brings over 20 years of R&D and commercial experience across multiple global companies to her new role at Cargene, including building differentiated product portfolios, developing strategic opportunities and successfully commercializing innovative therapies.

Kathy He, CEO of Cargene Biopharma
Kathy He, CEO of Cargene Biopharma

Situated at Singapore, Boston and Shanghai, Cargene Biopharma aims to leverage its new knowledge in biology and chemistry to develop highly specific, stable and potent nucleic acid-based therapies for a wide range of diseases. In December 2021the Company successfully closed a pre-Series A funding round of nearly $20 millionled by BioTrack Capital.

“My co-founder, Yann Chong Tan, and I’m thrilled to have Kathy join us as CEO and partner. The vast United States and China cross-border business leadership experience and successful experience in global capital markets are essential for us as we build a global biotech business,” said XQ Lin, Co-Founder and Chairman of the Board of Cargene.

Kathy joined Cargene from Kira Pharmaceuticals, a cross-border US-China biotechnology company. At Kira Pharmaceuticals, Kathy served as Global Chief Commercial Officer (CBO) and Managing Director of Chinawhere she led the closing of her $60 million Series B+ funding round by leading global investors and builds an efficient structure China deal to support the company’s global expansion.

Prior to Kira Pharmaceuticals, Kathy was CBO and Head of Corporate Development at HKEX-listed Abbisko Therapeutics, where she raised over $100 million and entered into a series of cross-border strategic partnerships. Early in her career, she held various strategic and commercial positions at Takeda Pharmaceuticals, Merck & Co. and Abbott Laboratories in the USA. In addition to extensive operational experience, Kathy has also worked as a managing director and venture capital partner in several cross-border investment firms.

“Oligonucleotide therapies have greatly expanded our toolbox for treating conditions that lack drug targets and therefore have no effective treatments. Cargene’s approach to combining its siRNA platform with novel first-in-class targets is rooted in its deep expertise in oligonucleotide science and access to breakthrough in basic biology research. says Kathy. “I am excited about the opportunity to leverage Cargene’s scientific capabilities to address significant unmet medical needs and grateful to work with the team to redefine the therapeutics of tomorrow. She added.

Kathy earned a bachelor’s degree in biology from Wuhan University, a master’s degree in molecular biology from University of Illinois at Urbana-Champaignand MBA from the Kellogg School of Management in Northwestern University. She is currently a board member of Diagnostic Photonics, an innovative medical device company, former director of Illinois Academy of Mathematics and Sciencesand former board member of the BayHelix Group, a non-profit professional organization for business leaders in the life sciences and healthcare industries.

About Cecil Cobb

Check Also

Author Joe Belcastro attends book conventions across the country to promote his novel, DOMINATURE

TAMPA, FL – Joe Belcastro is on tour for his debut novel DOMINATURE: What If …